Payment overview · 2025
General Payments
$1,862.04
97 reported records · 25 companies
Healthcare provider profile · identity verified
Yolanda Marcos, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAN ANTONIO, TX · NPI 1104845445
Verified facts
What the public records show
CMS Open Payments records show Yolanda Marcos, MD received $1,862.04 in general payments during 2025 across 97 reported records.
ABBVIE INC. accounted for 16.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Jardiance, Ozempic, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 341 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $298.18 | 16.0% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $170.83 | 9.2% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $154.89 | 8.3% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $145.96 | 7.8% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $138.21 | 7.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $131.69 | 7.1% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $100.91 | 5.4% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $96.11 | 5.2% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $95.01 | 5.1% | 4 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $64.11 | 3.4% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.76 | 3.2% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.92 | 2.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.35 | 2.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $50.64 | 2.7% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $42.46 | 2.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $36.92 | 2.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $28.54 | 1.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.92 | 1.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.47 | 1.1% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $19.56 | 1.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.15 | 1.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.46 | 1.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.49 | 0.8% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $14.34 | 0.8% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.16 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,862.04 | 97 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $174.85 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $145.96 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $143.80 | 14 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $138.21 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $123.33 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $121.14 | 12 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $107.42 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $98.91 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $96.11 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $95.01 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $75.66 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $74.49 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $74.49 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $64.11 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $63.41 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $56.85 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $56.03 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $56.03 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $52.92 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $50.64 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.90 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $45.90 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $44.06 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $42.46 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $36.92 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.32 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $28.54 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.92 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $11.09 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $11.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 341 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 65 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 87 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 202 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
70 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
341 | 314 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
202 | 143 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
72 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 510 | 157 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 430 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 387 | 120 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 341 | 314 |
| Levothyroxine Sodium | Levothyroxine Sodium | 298 | 104 |
| Lisinopril | Lisinopril | 270 | 89 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 202 | 143 |
| Gabapentin | Gabapentin | 162 | 51 |
| Losartan Potassium | Losartan Potassium | 155 | 49 |
| Omeprazole | Omeprazole | 152 | 55 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 151 | 129 |
| Montelukast Sodium | Montelukast Sodium | 151 | 49 |
| Metformin Hcl | Metformin Hcl | 147 | 48 |
| Alprazolam | Alprazolam | 137 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 128 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 125 | 23 |
| Simvastatin | Simvastatin | 116 | 37 |
| Irbesartan | Irbesartan | 105 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 33 |
| Trazodone Hcl | Trazodone Hcl | 88 | 24 |
| Ozempic | Semaglutide | 87 | 18 |
| Alendronate Sodium | Alendronate Sodium | 84 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 80 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 25 |
| Bupropion Xl | Bupropion Hcl | 78 | 25 |
| Carvedilol | Carvedilol | 77 | 24 |
| Ezetimibe | Ezetimibe | 77 | 29 |
| Metformin Hcl Er | Metformin Hcl | 74 | 23 |
| Mounjaro | Tirzepatide | 72 | 12 |
| Furosemide | Furosemide | 70 | 30 |
| Synthroid | Levothyroxine Sodium | 70 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 25 |
| Farxiga | Dapagliflozin Propanediol | 65 | 15 |
| Meloxicam | Meloxicam | 63 | 21 |
| Famotidine | Famotidine | 62 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 21 |
| Valsartan | Valsartan | 58 | 18 |
| Sertraline Hcl | Sertraline Hcl | 57 | 20 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 56 | 19 |
| Lorazepam | Lorazepam | 54 | suppressed |
| Progesterone | Progesterone, Micronized | 54 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 20 |
| Spironolactone | Spironolactone | 52 | 21 |
| Ondansetron Odt | Ondansetron | 51 | 11 |
| Chlorthalidone | Chlorthalidone | 49 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 13 |
| Finasteride | Finasteride | 48 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 15 |
| Tramadol Hcl | Tramadol Hcl | 48 | 13 |
| Allopurinol | Allopurinol | 47 | 12 |
| Estradiol | Estradiol | 47 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 46 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 13 |
| Januvia | Sitagliptin Phosphate | 43 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 43 | suppressed |
| Tenivac | Tetanus-Diphtheria Toxoids/Pf | 43 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 13 |
| Celecoxib | Celecoxib | 41 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 40 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 39 | 12 |
| Risedronate Sodium | Risedronate Sodium | 38 | 15 |
| Ibuprofen | Ibuprofen | 35 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | 12 |
| Atenolol | Atenolol | 34 | 13 |
| Clonazepam | Clonazepam | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | 13 |
| Np Thyroid | Thyroid,pork | 32 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | 17 |
| Fluconazole | Fluconazole | 30 | suppressed |
| Eliquis | Apixaban | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Epinephrine | Epinephrine | 19 | 16 |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 16 |
| Trulicity | Dulaglutide | 19 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,862.04 · 97 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, INSPIRE, JARDIANCE, JATENZO, Korlym, LEQVIO, NEFFY, NEXLETOL, NP Thyroid 60, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, Symbravo, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error